Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Liabilities and Shareholders Equity rose 1983.31% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 3172.51%. This contributed to the annual value of $608.5 million for FY2024, which is 7799.27% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Liabilities and Shareholders Equity is $504.6 million, which was up 1983.31% from $538.8 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $608.5 million for Q4 2024, and its period low was $52.5 million during Q1 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $207.3 million (2023), whereas its average is $279.7 million.
  • In the last 5 years, Spyre Therapeutics' Liabilities and Shareholders Equity tumbled by 4916.69% in 2022 and then skyrocketed by 82959.79% in 2024.
  • Spyre Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $109.9 million in 2021, then tumbled by 35.28% to $71.1 million in 2022, then skyrocketed by 380.52% to $341.9 million in 2023, then soared by 77.99% to $608.5 million in 2024, then decreased by 17.07% to $504.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $504.6 million for Q3 2025, versus $538.8 million for Q2 2025 and $569.8 million for Q1 2025.